Market closed

Compass Therapeutics/$CMPX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Compass Therapeutics

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.

Ticker

$CMPX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Boston, United States

Employees

32
Website
www.compasstherapeutics.com

CMPX Metrics

BasicAdvanced
$268M
-
-$0.35
0.75
-

$268M

0.75

$2.68

$0.77

1.4M

31.838

30.544

4.567

4.969

-21.71%

-32.00%

310.065

1.94

1.94

-5.479

8.50%

-37.28%

What the Analysts think about CMPX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Compass Therapeutics stock.

CMPX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CMPX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

CMPX News

AllArticlesVideos
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

GlobeNewsWire·1 month ago
Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Seeking Alpha·1 month ago
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CMPX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Compass Therapeutics stock?

Compass Therapeutics (CMPX) has a market cap of $268M as of January 15, 2025.

What is the P/E ratio for Compass Therapeutics stock?

The price to earnings (P/E) ratio for Compass Therapeutics (CMPX) stock is 0 as of January 15, 2025.

Does Compass Therapeutics stock pay dividends?

No, Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Compass Therapeutics dividend payment date?

Compass Therapeutics (CMPX) stock does not pay dividends to its shareholders.

What is the beta indicator for Compass Therapeutics?

Compass Therapeutics (CMPX) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.